Based on the Alterity Therapeutics Limited stock forecast from 0 analysts, the average analyst target price for Alterity Therapeutics Limited is not available over the next 12 months. Alterity Therapeutics Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alterity Therapeutics Limited is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Alterity Therapeutics Limited’s stock price was EUR 0.01. Alterity Therapeutics Limited’s stock price has changed by +20.00% over the past week, -36.84% over the past month and +100.00% over the last year.
No recent analyst target price found for Alterity Therapeutics Limited
No recent average analyst rating found for Alterity Therapeutics Limited
Company Overview Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Read Less
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug cand...Read More
Frequently Asked Questions About Alterity Therapeutics Limited (PBN:F) Stock
Stock Target Advisor's fundamental analysis for Alterity Therapeutics Limited's stock is Bearish.
Unfortunately we do not have enough data on PBN:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBN:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBN:F's stock to indicate if its overvalued.
The last closing price of PBN:F's stock was EUR 0.01.
The most recent market capitalization for PBN:F is EUR 0.05B.
Unfortunately we do not have enough analyst data on PBN:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Alterity Therapeutics Limited's stock.
As per our most recent records Alterity Therapeutics Limited has 10 Employees.
Alterity Therapeutics Limited's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Limited's website at https://alteritytherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Alterity Therapeutics Limited (PBN:F) Stock
Stock Target Advisor's fundamental analysis for Alterity Therapeutics Limited's stock is Bearish.
Unfortunately we do not have enough data on PBN:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBN:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBN:F's stock to indicate if its overvalued.
The last closing price of PBN:F's stock was EUR 0.01.
The most recent market capitalization for PBN:F is EUR 0.05B.
Unfortunately we do not have enough analyst data on PBN:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Alterity Therapeutics Limited's stock.
As per our most recent records Alterity Therapeutics Limited has 10 Employees.
Alterity Therapeutics Limited's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Limited's website at https://alteritytherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PBN:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
